Marinus Pharmaceuticals, Inc.

NasdaqGM:MRNS 株式レポート

時価総額：US$30.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Marinus Pharmaceuticals マネジメント

マネジメント 基準チェック /24

Marinus Pharmaceuticalsの CEO はScott Braunsteinで、 Aug2019年に任命され、 の在任期間は 5.5年です。 の年間総報酬は$ 3.21Mで、 20.2%給与と79.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.22%を直接所有しており、その価値は$ 65.46K 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と3.6年です。

主要情報

Scott Braunstein

最高経営責任者

US$3.2m

報酬総額

CEO給与比率20.22%
CEO在任期間5.5yrs
CEOの所有権0.2%
経営陣の平均在職期間4.3yrs
取締役会の平均在任期間3.6yrs

経営陣の近況

Recent updates

分析記事 • Sep 20

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

It's not a stretch to say that Marinus Pharmaceuticals, Inc.'s ( NASDAQ:MRNS ) price-to-sales (or "P/S") ratio of 2.9x...
分析記事 • Aug 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest quarterly results, disappointing...
分析記事 • May 11

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) just released its latest first-quarter report and things are not looking...
分析記事 • Apr 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

The Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) share price has fared very poorly over the last month, falling by a...
分析記事 • Mar 08

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest annual results, disappointing...
分析記事 • Dec 22

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Sep 22

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Jun 12

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...
分析記事 • May 16

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

Shareholders in Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) may be thrilled to learn that the analysts have just...
分析記事 • Oct 26

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

One thing we could say about the analysts on Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) - they aren't optimistic...
分析記事 • Oct 12

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Sep 22

Marinus Pharmaceuticals: Positive News Flow Of Note

Summary Today, we put Marinus Pharmaceuticals back in the spotlight as the stock has held up well even as the market has sold off. The company also has seen some positive news flow of late including the sale of a priority review voucher and some additional cash flow from BARDA. An investment analysis follows in the paragraphs below. Humility means accepting reality with no attempt to outsmart it.”― David Richo When we last revisited Marinus Pharmaceuticals, Inc. (MRNS) in May, we recommended it for a small covered call position. That seems to have been a prudent call to this point as the stock is basically trading flat/slightly up to when we last looked at it. Given how poorly biotech stocks have traded in 2022, that marks a victory. Seeking Alpha We are circling back today to update the investment thesis around Marinus as the company has seen some positive news flow in recent weeks. An analysis follows below. Company Overview: Marinus Pharmaceuticals is focused on the development of therapies for the treatment of rare genetic epilepsies and other seizure disorders. The company is based outside of Philadelphia, PA. The stock trades for around $6.50 a share and sports an approximate market capitalization of $260 million. May Company Presentation The company has one primary asset under development for multiple indications called ganaxolone. This compound is also known by its brand name Ztalmy was approved this March for seizures associated with cyclin-dependent-kinase like 5 (CDKL5) deficiency disorder (CDD). The marketing application for Ztalmy in Europe is currently undergoing review by the European Medicines Agency or EMA. The company plans to submit complete responses to questions from the EMA in November and they should render a decision in the first quarter of next year. May Company Presentation Recent Developments for Marinus: The priority review voucher Marinus garnered via the approval of Ztalmy by the FDA was sold at the end of August for $110 million. This bolstered the company's cash reserves substantially and was right in the range ($100 million to $125 million) these vouchers have received in recent years. In addition, it was announced that Biomedical Advanced Research and Development Authority or BARDA had exercised its first contract option worth ~$12.3M, to support U.S. onshoring of manufacturing capabilities of Ztalmy. That still leaves some $39 million of potential awards under this contract, $21 million in previously approved base-period funding and up to $18 million across two additional option periods. Company Website The company continues to advance ganaxolone against other indications. Marinus has a Phase 3 trial "RAISE" to evaluate ganaxolone to treat Refractory Status Epilepticus or RSE. Topline results from this study should be out in the second half of 2023. This study is being funded by BARDA. May Company Presentation Recently the first patient was randomized and dosed in a Phase 3 trial to evaluate ganaxolone to treat Tuberous Sclerosis Complex or TSC. The study will consist of approximately targeting 80 clinical sites and topline results are not expected until the first quarter of 2024 at the earliest. May Company Presentation Results from a Phase 2 study around RSE was published in June and a Phase 3 study for RSE 'RAISE II' (for European registration) is expected to begin enrollment in the second half of 2023. May Company Presentation A Phase 2 trial 'RESET' evaluating ganaxolone in established status epilepticus on track to begin U.S. enrollment in the second half of this year. A Phase 2 trial to evaluate ganaloxone to treat Lennox-Gastaut syndrome is now targeted to begin in 2023. Analyst Commentary & Balance Sheet: The analyst community also seems to be turning more sanguine on Marinus' story. Over the past five weeks, four analyst firms including Robert W. Baird and JMP Securities have reissued Buy ratings on MRNS. Price targets proffered range from $17 to $32 a share. Approximately five percent of the outstanding float is currently held short. There has been no insider activity in this equity since March of 2021. The company ended the second quarter of this year with just over $90 million in cash and marketable securities on its balance sheet after posting a net loss of $39.4 million in the quarter. With the receipts from the priority review voucher in hand, management believes current funding levels are sufficient to fund it into the fourth quarter of 2023. Marinus has approximately $70 million of long term debt. Verdict: There are a wide range of sales and earnings estimates from the analyst community at the present time. Right now they expect the company to lose just over two bucks a share in FY2022 and over $3.50 a share in FY2023 as the company spends big on the rollout of Ztalmy and advancing its pipeline. Revenue estimates range from approximately $15 million to $60 million next fiscal year. The company had just $1.8 million worth of revenue in the second quarter.
Seeking Alpha • Aug 29

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Marinus Pharmaceuticals (NASDAQ:MRNS) on Monday said it had closed on the sale of a U.S. FDA voucher for $110M. The voucher, called the Rare Pediatric Disease Priority Review Voucher, entitles MRNS to a priority review from the agency and proceeds to carry out its drug development activities with an aim to treat rare pediatric diseases. MRNS said it had received the $110M of gross funds, which are in addition to the $92.3M the had reported in cash and cash equivalents as of June 30. The company said it would use the proceeds from the closing of the sale on the voucher for the commercial launch of seizure treatment Ztalmy, execution of its phase 3 clinical programs and other general expenditures. With the addition of this funding, MRNS said it now expects to fund its expenses and requirements and maintain the minimum cash balance required under its debt facility into Q4 2023. MRNS stock +4.2% to $6.97 after hours.
分析記事 • Aug 13

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Aug 10

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.93 (-43.1% Y/Y) and the consensus Revenue Estimate is $2.31M (+20.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Jul 28

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Marinus Pharmaceuticals (NASDAQ:MRNS) on Thursday announced the U.S. commercial launch of Ztalmy for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. CDD is a genetic disorder caused due to mutations in the CDKL5 gene. It is characterized by seizures, developmental delay and intellectual disability. Ztalmy, which is an oral treatment, got U.S. FDA approval earlier this year in March. Marinus (MRNS) also said it had established a patient support program called Ztalmy One which facilitates access to the treatment, including prescription benefits and financial support for patients with no insurance.
Seeking Alpha • May 05

Revisiting Marinus Pharmaceuticals

Today, we put biopharma concern Marinus Pharmaceuticals back in the spotlight for the first time in more than a year. Despite the fall in the stock recently, analyst firms remain strongly positive on the shares. An updated investment analysis follows in the paragraphs below.

CEO報酬分析

Marinus Pharmaceuticals の収益と比較して、Scott Braunstein の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$140m

Jun 30 2024n/an/a

-US$149m

Mar 31 2024n/an/a

-US$145m

Dec 31 2023US$3mUS$650k

-US$141m

Sep 30 2023n/an/a

-US$134m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$3mUS$591k

-US$20m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$4mUS$574k

-US$99m

Sep 30 2021n/an/a

-US$88m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$76m

Dec 31 2020US$4mUS$556k

-US$76m

Sep 30 2020n/an/a

-US$74m

Jun 30 2020n/an/a

-US$72m

Mar 31 2020n/an/a

-US$69m

Dec 31 2019US$2mUS$305k

-US$54m

Sep 30 2019n/an/a

-US$49m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018US$210kn/a

-US$37m

報酬と市場: Scottの 総報酬 ($USD 3.21M ) は、 US市場 ($USD 647.55K ) の同規模の企業の平均を上回っています。

報酬と収益: Scottの報酬は増加しましたが、会社は利益を上げていません。

CEO

Scott Braunstein (61 yo)

5.5yrs
在職期間
US$3,214,100
報酬

Dr. Scott N. Braunstein, M.D., has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Scott Braunstein
CEO, President & Chairman5.5yrsUS$3.21m0.22%
$ 65.5k
Steven Pfanstiel
COO, CFO & Treasurer3.8yrsUS$1.44m0.031%
$ 9.5k
Joseph Hulihan
Chief Medical Officer5.3yrsUS$1.37m0.031%
$ 9.4k
Alex Aimetti
Chief Scientific Officerno dataデータなしデータなし
Sonya Weigle
Senior VP of Investor Relations1.7yrsデータなしデータなし
Martha Manning
Senior VP4.7yrsデータなし0.022%
$ 6.7k
Molly Cameron
Director of Corporate Communications & Investor Relations1.7yrsデータなしデータなし
Kimberly McCormick
Chief Regulatory & Quality Assurance Officerno dataデータなしデータなし
Christina Shafer
Chief Commercial Officer4.3yrsデータなし0.034%
$ 10.3k
David Czekai
Chief Chemistryno dataデータなしデータなし
4.3yrs
平均在職期間
61yo
平均年齢

経験豊富な経営陣: MRNSの経営陣は 経験豊富 であると考えられます ( 4.3年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Scott Braunstein
CEO, President & Chairman6.4yrsUS$3.21m0.22%
$ 65.5k
Timothy Mayleben
Lead Independent Director16.2yrsUS$202.52k0.025%
$ 7.7k
Elan Ezickson
Independent Director5.2yrsUS$162.52k0.016%
$ 4.7k
Jacqueline A. French
Member of Scientific Advisory Boardno dataデータなしデータなし
Seth H. Fischer
Independent Director8.4yrsUS$160.02k0.011%
$ 3.3k
Michael Rogawski
Member of Scientific Advisory Boardno dataデータなしデータなし
Christine Silverstein
Independent Director2.1yrsUS$249.21kデータなし
Marvin Johnson
Independent Director1.8yrsUS$304.81k0.0098%
$ 3.0k
Eugen Trinka
Member of Scientific Advisory Boardno dataデータなしデータなし
Elia M. Knight
Member of Scientific Advisory Boardno dataデータなしデータなし
Rajsekar Rajaraman
Member of the Scientific Advisory Boardless than a yearデータなしデータなし
Joseph Sullivan
Member of the Scientific Advisory Boardless than a yearデータなしデータなし
3.6yrs
平均在職期間
61yo
平均年齢

経験豊富なボード: MRNSの 取締役会 は 経験豊富 であると考えられます ( 3.6年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2025/02/10 20:20
終値2025/02/07 00:00
収益2024/09/30
年間収益2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Marinus Pharmaceuticals, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7

アナリスト機関
Kimberly LeeBrean Capital Historical (Janney Montgomery)
François BriseboisCraig-Hallum Capital Group LLC
Douglas TsaoH.C. Wainwright & Co.